WO2023027670A3 - Compositions de lévosimendan lyophilisées - Google Patents

Compositions de lévosimendan lyophilisées Download PDF

Info

Publication number
WO2023027670A3
WO2023027670A3 PCT/TR2022/050883 TR2022050883W WO2023027670A3 WO 2023027670 A3 WO2023027670 A3 WO 2023027670A3 TR 2022050883 W TR2022050883 W TR 2022050883W WO 2023027670 A3 WO2023027670 A3 WO 2023027670A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
levosimendan
lyophilized
kollidon
tri
Prior art date
Application number
PCT/TR2022/050883
Other languages
English (en)
Other versions
WO2023027670A2 (fr
Inventor
Samiye FICICIOGLU
Celil ULUTURK
Original Assignee
Tum Ekip Ilac Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2021/013305 external-priority patent/TR2021013305A2/tr
Application filed by Tum Ekip Ilac Anonim Sirketi filed Critical Tum Ekip Ilac Anonim Sirketi
Publication of WO2023027670A2 publication Critical patent/WO2023027670A2/fr
Publication of WO2023027670A3 publication Critical patent/WO2023027670A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne les compositions pharmaceutiques sous forme de poudre lyophilisée, qui ne contiennent pas d'alcool, comprenant du lévosimendan en tant que principe actif ou un sel pharmaceutiquement acceptable de celui-ci, du Kollidon PF-17 en tant qu'agent de solubilisation et du citrate trisodique en tant qu'agent tampon, la préparation et l'utilisation de ces compositions.
PCT/TR2022/050883 2021-08-23 2022-08-20 Compositions de lévosimendan lyophilisées WO2023027670A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2021/013305 TR2021013305A2 (tr) 2021-08-23 Li̇yofi̇li̇ze levosi̇mendan formülasyonlari
TR2021013305 2021-08-23

Publications (2)

Publication Number Publication Date
WO2023027670A2 WO2023027670A2 (fr) 2023-03-02
WO2023027670A3 true WO2023027670A3 (fr) 2023-05-11

Family

ID=85323520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2022/050883 WO2023027670A2 (fr) 2021-08-23 2022-08-20 Compositions de lévosimendan lyophilisées

Country Status (1)

Country Link
WO (1) WO2023027670A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116473930B (zh) * 2023-05-17 2023-12-15 山东泰合医药科技有限公司 一种注射用左西孟旦及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346273B1 (en) * 1997-07-23 2002-02-12 Farmigea S.P.A. Process for solubilizing pharmaceutically active ingredients in water and in aqueous vehicles
EP1210085A2 (fr) * 1999-09-10 2002-06-05 Orion Corporation Solutions pharmaceutiques de levosimendan
WO2018085476A1 (fr) * 2016-11-02 2018-05-11 Centrexion Therapeutics Corporation Formulations injectables aqueuses stables de capsaïcine et leurs utilisations médicales

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346273B1 (en) * 1997-07-23 2002-02-12 Farmigea S.P.A. Process for solubilizing pharmaceutically active ingredients in water and in aqueous vehicles
EP1210085A2 (fr) * 1999-09-10 2002-06-05 Orion Corporation Solutions pharmaceutiques de levosimendan
WO2018085476A1 (fr) * 2016-11-02 2018-05-11 Centrexion Therapeutics Corporation Formulations injectables aqueuses stables de capsaïcine et leurs utilisations médicales

Also Published As

Publication number Publication date
WO2023027670A2 (fr) 2023-03-02

Similar Documents

Publication Publication Date Title
MX2024007720A (es) Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
WO2019036008A8 (fr) Lipides destinés à être utilisés dans des formulations nanoparticulaires lipidiques
OA12806A (en) Novel perindopril salt and pharmaceutical compositions containing same.
WO2018165404A8 (fr) Formulations pharmaceutiques de phloroglucinol et de triméthylphloroglucinol
HUP0302319A2 (hu) Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására
RS50937B (sr) Farmaceutska kompozicija koja sadrži metformin i glibenklamid za lečenje šećerne bolesti tipa ii
HUP0000587A1 (hu) Takrolimuszt (FK506) tartalmazó gyógyszerkészítmény
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2023012376A3 (fr) Prévention de la conversion d'agents pharmaceutiques en composés de n-nitrosamine toxiques
WO2023027670A3 (fr) Compositions de lévosimendan lyophilisées
MX2021010144A (es) Formulaciones farmaceuticas.
MX2022006940A (es) Composiciones farmaceuticas.
WO2007011989A3 (fr) Multiples principes actifs pharmaceutiques combines dans des particules d'inhalation discretes et leurs formulations
WO2012085284A3 (fr) Formulations pharmaceutiques à charge médicamenteuse élevée comprenant de la dronédarone et des sels pharmaceutiquement acceptables de celles-ci
WO2019203771A3 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la sitagliptine
WO2020013777A3 (fr) Formulations de comprimés comprenant de la metformine et de la sitagliptine
UA106361C2 (ru) Фармацевтическая композиция для лечения эссенциальной тромбоцитемии
MX2017004476A (es) Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion.
WO2006053089A3 (fr) Methodes et formulations permettant de preparer des compositions pharmaceutiques contenant du bupropion
HRP20201436T1 (hr) Makrogoli za davanje na sluznicu i njihove terapeutske primjene
WO2020025742A9 (fr) Formulation à libération immédiate d'une triple combinaison d'ingrédients pharmaceutiques actifs utile dans le traitement du syndrome des ovaires polykystiques
ES2266502T3 (es) Composicion de relleno sinergetica.
WO2018069805A3 (fr) Procédé de préparation d'une composition liquide de l-thyroxine à usage oral
CA2455710A1 (fr) Sels calciques exercant une activite cytotoxique
CA3188980A1 (fr) Compositions de phytonadione

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE